Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Natera $287.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc…
Nevro $346 million concurrent offerings of stock and convertible senior notes
Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189…
InnoCare Pharma HK$2.24 billion IPO
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock…
Cigna $3.5 billion senior notes offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of $1…
Kala Pharmaceuticals $126.2 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
McKesson splits off interest in Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offer by McKesson to exchange shares of McKesson common stock…
NanoString Technologies $230 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of …
Millendo Therapeutics amendments of at-the-market offering program
Davis Polk advised the sales agents in connection with certain amendments of the SEC-registered at-the-market offering…
J M Smith sale of smith Technologies to Francisco Partners
Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies,…
NuVasive $450 million convertible senior notes offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NuVasive, Inc. of $450 million…